lutetium has been researched along with gallium ga 68 dotatate in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aldridge, M; Bomanji, J; Fersht, N; Maclean, J; Short, S | 1 |
| Ballinger, JR | 1 |
| Courbon, F; Dierickx, L; Vija, L | 1 |
1 review(s) available for lutetium and gallium ga 68 dotatate
| Article | Year |
|---|---|
Theranostic radiopharmaceuticals: established agents in current use.
Topics: 3-Iodobenzylguanidine; Antigens, CD20; Bone Neoplasms; Dipeptides; Diphosphonates; Drug Approval; Forecasting; Heterocyclic Compounds, 1-Ring; Hodgkin Disease; Humans; Iodine Radioisotopes; Lutetium; Octreotide; Organometallic Compounds; Prostate-Specific Antigen; Radiopharmaceuticals; Somatostatin; Theranostic Nanomedicine; Thyroid Diseases | 2018 |
2 other study(ies) available for lutetium and gallium ga 68 dotatate
| Article | Year |
|---|---|
Peptide receptor radionuclide therapy for aggressive atypical pituitary adenoma/carcinoma: variable clinical response in preliminary evaluation.
Topics: Adult; Growth Hormone-Secreting Pituitary Adenoma; Humans; Lutetium; Male; Middle Aged; Octreotide; Organometallic Compounds; Pituitary Neoplasms; Positron-Emission Tomography; Prolactinoma; Radioisotopes; Radiopharmaceuticals; Receptors, Peptide; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed | 2014 |
Receptor radionuclide targeting for neuroendocrine tumors (NET) diagnostic and therapy.
Topics: Clinical Trials, Phase III as Topic; France; Humans; Lutetium; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Positron-Emission Tomography; Precision Medicine; Radioisotopes; Radiopharmaceuticals; Radiotherapy; Receptors, Somatostatin | 2019 |